Search research articles
Contact Us
Filters
Showing results (221-230 of 265) with videos related to
Page
of 27
Sort By:
European Journal of Cancer (Oxford, England : 1990)
|
July 24, 2023
Adjuvant treatment and outcome of stage III melanoma patients: Results of a multicenter real-world German Dermatologic Cooperative Oncology Group (DeCOG) study
Georg C Lodde, Jessica Hassel, Lena M Wulfken, et al.
European Journal of Cancer (Oxford, England : 1990)
|
February 26, 2026
Treatment patterns in geriatric patients with melanoma and the effect of age on the efficacy of immunotherapy: Analysis from the real-world multicenter registry ADOREG
Konstantinos Lallas, Lena Nanz, Selma Ugurel, et al.
European Journal of Cancer (Oxford, England : 1990)
|
February 26, 2026
Real-world data on anti-PD-1 plus lenvatinib as a treatment option in pretreated advanced melanoma patients - a retrospective DeCOG study
Lea Jessica Albrecht, Jana Garnier, Anne Zaremba, et al.
European Journal of Cancer (Oxford, England : 1990)
|
July 17, 2024
Shortened progression free and overall survival to immune-checkpoint inhibitors in BRAF-, RAS- and NF1- ("Triple") wild type melanomas
Philipp Jansen, Wolfgang Galetzka, Georg C Lodde, et al.
European Journal of Cancer (Oxford, England : 1990)
|
June 28, 2025
Real-world experience with first- versus second-line cemiplimab for advanced basal cell carcinoma
Viola K DeTemple, Martin Kaatz, Eggert Stockfleth, et al.
European Journal of Cancer (Oxford, England : 1990)
|
May 28, 2023
Immune checkpoint inhibition in patients with NRAS mutated and NRAS wild type melanoma: a multicenter Dermatologic Cooperative Oncology Group study on 637 patients from the prospective skin cancer registry ADOREG
Anne Zaremba, Peter Mohr, Ralf Gutzmer, et al.
Ebiomedicine
|
September 3, 2023
Correlation of tumor PD-L1 expression in different tissue types and outcome of PD-1-based immunotherapy in metastatic melanoma - analysis of the DeCOG prospective multicenter cohort study ADOREG/TRIM
Jan-Malte Placke, Mona Kimmig, Klaus Griewank, et al.
Frontiers in Immunology
|
June 25, 2024
Optimizing immune checkpoint blockade in metastatic uveal melanoma: exploring the association of overall survival and the occurrence of adverse events
Elias A T Koch, Anne Petzold, Edgar Dippel, et al.
Journal of the European Academy of Dermatology and Venereology : JEADV
|
January 30, 2026
Role of comorbidities and medication on immunotherapy efficacy in cSCC: A DeCOG multicentre analysis
Glenn Geidel, Sabrina Bänsch, Laura Adam, et al.
Journal for Immunotherapy of Cancer
|
October 23, 2020
Immune checkpoint inhibition therapy for advanced skin cancer in patients with concomitant hematological malignancy: a retrospective multicenter DeCOG study of 84 patients
Ulrike Leiter, Carmen Loquai, Lydia Reinhardt, et al.
Page
of 27
Search research articles
Search
Showing results (221-230 of 265) with videos related to
Sort By:
Page
of 27
European Journal of Cancer (Oxford, England : 1990)
|
July 24, 2023
Adjuvant treatment and outcome of stage III melanoma patients: Results of a multicenter real-world German Dermatologic Cooperative Oncology Group (DeCOG) study
Georg C Lodde, Jessica Hassel, Lena M Wulfken, et al.
European Journal of Cancer (Oxford, England : 1990)
|
February 26, 2026
Treatment patterns in geriatric patients with melanoma and the effect of age on the efficacy of immunotherapy: Analysis from the real-world multicenter registry ADOREG
Konstantinos Lallas, Lena Nanz, Selma Ugurel, et al.
European Journal of Cancer (Oxford, England : 1990)
|
February 26, 2026
Real-world data on anti-PD-1 plus lenvatinib as a treatment option in pretreated advanced melanoma patients - a retrospective DeCOG study
Lea Jessica Albrecht, Jana Garnier, Anne Zaremba, et al.
European Journal of Cancer (Oxford, England : 1990)
|
July 17, 2024
Shortened progression free and overall survival to immune-checkpoint inhibitors in BRAF-, RAS- and NF1- ("Triple") wild type melanomas
Philipp Jansen, Wolfgang Galetzka, Georg C Lodde, et al.
European Journal of Cancer (Oxford, England : 1990)
|
June 28, 2025
Real-world experience with first- versus second-line cemiplimab for advanced basal cell carcinoma
Viola K DeTemple, Martin Kaatz, Eggert Stockfleth, et al.
European Journal of Cancer (Oxford, England : 1990)
|
May 28, 2023
Immune checkpoint inhibition in patients with NRAS mutated and NRAS wild type melanoma: a multicenter Dermatologic Cooperative Oncology Group study on 637 patients from the prospective skin cancer registry ADOREG
Anne Zaremba, Peter Mohr, Ralf Gutzmer, et al.
Ebiomedicine
|
September 3, 2023
Correlation of tumor PD-L1 expression in different tissue types and outcome of PD-1-based immunotherapy in metastatic melanoma - analysis of the DeCOG prospective multicenter cohort study ADOREG/TRIM
Jan-Malte Placke, Mona Kimmig, Klaus Griewank, et al.
Frontiers in Immunology
|
June 25, 2024
Optimizing immune checkpoint blockade in metastatic uveal melanoma: exploring the association of overall survival and the occurrence of adverse events
Elias A T Koch, Anne Petzold, Edgar Dippel, et al.
Journal of the European Academy of Dermatology and Venereology : JEADV
|
January 30, 2026
Role of comorbidities and medication on immunotherapy efficacy in cSCC: A DeCOG multicentre analysis
Glenn Geidel, Sabrina Bänsch, Laura Adam, et al.
Journal for Immunotherapy of Cancer
|
October 23, 2020
Immune checkpoint inhibition therapy for advanced skin cancer in patients with concomitant hematological malignancy: a retrospective multicenter DeCOG study of 84 patients
Ulrike Leiter, Carmen Loquai, Lydia Reinhardt, et al.
Page
of 27